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Abstract
Ischemic stroke is the leading cause of disability, and effective therapeutic strategies are needed to promote complete
recovery. Neuroinflammation plays a significant role in stroke pathophysiology, and there is limited understanding of how it
affects recovery. The aim of this study was to characterize the spatiotemporal expression profile of microglial activation and
whether dampening microglial/macrophage activation post-stroke facilitates the recovery. For dampening microglial/
macrophage activation, we chose intranasal administration of naloxone, a drug that is already in clinical use for opioid
overdose and is known to decrease microglia/macrophage activation. We characterized the temporal progression of
microglia/macrophage activation following cortical ischemic injury in rat and found the peak activation in cortex 7 d
post-stroke. Unexpectedly, there was a chronic expression of phagocytic cells in the thalamus associated with neuronal
loss. ()-Naloxone, an enantiomer that reduces microglial activation without antagonizing opioid receptors, was adminis-
tered intranasally starting 1 d post-stroke and continuing for 7 d. ()-Naloxone treatment decreased microglia/macrophage
activation in the striatum and thalamus, promoted behavioral recovery during the 14-d monitoring period, and reduced
neuronal death in the lesioned cortex and ipsilateral thalamus. Our results are the first to show that post-stroke intranasal
()-naloxone administration promotes short-term functional recovery and reduces microglia/macrophage activation. There-
fore, ()-naloxone is a promising drug for the treatment of ischemic stroke, and further studies should be conducted.
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Significance Statement
Ischemic stroke is one of the leading causes of adult disability, and new drug treatments are needed, as
there is no drug that promotes recovery. Neuroinflammation is suggested to play a role in the recovery
process. Naloxone is a drug used clinically to treat opioid overdose. Its opioid receptor inactive form,
()-naloxone, is known to reduce the activation of microglia, the immune cells of the brain. We show for the
first time that repeated dosing of intranasal ()-naloxone starting 1 d after stroke promotes short-term
recovery in rats and reduces microglial activation and neuronal loss in the stroke brain. Our finding could
be important for future stroke treatment and encourages further testing of ()-naloxone in stroke patients.
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Introduction
Approximately 10 million patients survive a stroke each
year; however, there are currently no pharmacological
options to promote recovery. Neurologic deficits including
impaired use of contralateral limbs, sensory and cognitive
deficits, and problems in speaking are the primary cause
of disability and remain without effective treatment. De-
spite increased knowledge of the cellular and molecular
mechanisms that mediate damage and recovery after
stroke, the development of new drugs for stroke has been
unsuccessful (Dirnagl, 2012). Most studies have focused
on neuroprotection, and therefore, there is a great need to
find novel drug targets and develop new treatments that
would improve the recovery from ischemic brain injury by
targeting postischemic pathologic mechanisms such as
inflammation. Modulation of brain inflammatory cascades
following stroke is recognized as a viable therapeutic
strategy to promote functional recovery from ischemic
brain injury (Endres et al., 2008). However, very few stud-
ies have taken this approach, and little is known about
recovery from stroke in relation to neuroinflammation.
The drug naloxone, an opiate antagonist, has been
clinically used for opioid overdose for nearly 50 years, has
anti-inflammatory properties, and can attenuate microglial
activation. Naloxone has two stereoisomers, the (–) and
() enantiomers (Fig. 1). (–)-Naloxone has a high affinity
for antagonizing , , and  opioid receptors, whereas
()-naloxone has a very low affinity for opioid receptors
(Iijima et al., 1978). Clinical reports indicate that intrave-
nously administered (–)-naloxone ameliorates neurologic
deficits in acute stroke (Baskin and Hosobuchi, 1981;
Jabaily and Davis, 1984). Studies examining the neuro-
protective effect of (–)-naloxone in rat focal cerebral isch-
emia also showed a significant reduction in neuronal loss
and inflammation (Chen et al., 2001; Liao et al., 2003), but
()-naloxone did not affect infarction volume when ad-
ministered before ischemia. These differences between
(–) and () isoforms suggest a role for opioid receptor
antagonism in the neuroprotective effect (Liao et al.,
2003). However, both enantiomers have been shown to
reduce the number of activated microglia in a rat model of
neuropathic pain (Hutchinson et al., 2008) and to inhibit
superoxide production from microglia, and subsequent
neurodegeneration, by interacting with NADPH oxidase
(Liu et al., 2002; Qin et al., 2005; Wang et al., 2012). Also,
both naloxone enantiomers reduce lipopolysaccharide
(LPS)-induced microglial activation and protect neurons
from LPS-induced neurodegeneration (Liu et al., 2000a, b,
c). LPS signaling in microglia/macrophages requires Toll-like
receptor 4 (TLR4) that is expressed abundantly on microglia
(Lehnardt et al., 2003). Both (–)- and ()-naloxone enantiom-
ers decrease LPS-induced TLR4 signaling (Hutchinson
et al., 2008; Wang et al., 2016) and both have been shown to
antagonize the TLR4 coreceptor MD2 (Hutchinson et al.,
2012). TLR4 activation leads to activation of NF-B and
production of pro-inflammatory cytokines, interferons, and
reactive oxygen/nitrogen species. TLR4 deficiency is neuro-
protective in ischemic stroke in mice (Kilic et al., 2008), and
increased TLR4 expression is associated with more severe
stroke in patients (Yang et al., 2008).
Collectively, these studies suggest that naloxone can
modulate immune and glial responses and has therapeu-
tic potential in stroke. However, its effects on post-stroke
microglial activation and recovery have not been studied.
Because () and (–) forms have similar efficacy in reduc-
ing microglial activation, the advantage of the ()-form is
that side effects from antagonizing opioid receptors can
be avoided. Thus, we aimed to study whether prolonged
post-stroke administration of ()-naloxone in rats would
promote recovery and whether this recovery is associated
with altered levels of activated microglia/macrophages.
Furthermore, we took an approach of intranasal adminis-
tration, since recent advances with intranasal naloxone
formulations have provided excellent bioavailability and
enabled easy administration in patients. We first charac-
terized the neuroinflammatory response following focal
cortical ischemia-reperfusion injury, since it is not well
studied. As microglia/macrophages showed activation al-
ready on day 2 post-stroke in the ischemic cortex and
maximum activation was observed at day 7, we adminis-
tered ()-naloxone during this accumulation period. Here
we show how post-stroke intranasal ()-naloxone pro-
moted behavioral recovery during the short 14-d testing
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Figure 1. Chemical structure of (–)-naloxone and ()-
naloxone enantiomers. Ki of (–)-naloxone for antagonizing opi-
oid receptors is in the 1 nM range, whereas ()-naloxone has a
very low affinity for opioid receptors, with a Ki of 10,000 nM
(Iijima et al., 1978).
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Food and water were freely available in the home cage.
Experimental procedures were approved by the NIDA
Animal Care and Use Committee or by the National
Animal Experiment Board of Finland (protocol approval
number ESAVI/5459/04.10.03/2011) and followed the
guidelines of the “Guide for the Care and Use of Labora-
tory Animals” (National Institutes of Health publication,
1996) and local laws and regulations.
Cortical stroke model in rats with distal middle
cerebral artery occlusion
To model focal cortical ischemic stroke in rats, the
three-vessel occlusion method was used. In this model,
the stroke damage is restricted to the cortex, and the
relative size of the stroke is close to that of an average
human stroke (Delavaran et al., 2013). Ligation of the right
middle cerebral artery (MCA) and common carotid arteries
(CCAs) bilaterally was performed as described previously
(Chen et al., 1986; Airavaara et al., 2009, 2010; Harvey
et al., 2011). Briefly, rats were anesthetized with chloral
hydrate 0.4 g/kg intraperitoneally (i.p.). The bilateral CCAs
were identified and isolated through a ventral midline
cervical incision. The rats were placed in a stereotaxic
apparatus, and a craniotomy was performed to expose
the right MCA. The MCA was ligated with a 10-0 suture,
and bilateral CCAs were ligated with nontraumatic arterial
clamps. After 60 or 90 min of ischemia, the suture around
the MCA and arterial clips on CCAs were removed to
begin reperfusion. After recovery from anesthesia, rats
were returned to their home cage. Body temperature
during and after surgery was maintained at 37°C.
Intranasal administration of (–)-naloxone and ()-
naloxone
(–)-Naloxone and ()-naloxone were synthesized in the
laboratory of Dr. Kenner Rice (NIDA IRP, NIH). Dosing was
estimated from a previously published study (Hutchinson
et al., 2008). Drugs were administered intranasally under
isoflurane anesthesia (Anesthesia Auto Flow System; E-Z
Anesthesia) starting from post-stroke day 1 and were
continued at 12-h intervals for 7 d, a total of 14 times.
Briefly, animals were placed in the induction chamber for
1–1.5 min, and 5% isoflurane was delivered at 1000 cc/
min. Animals were transferred to the nose cone where
they received 1.5% isoflurane delivered at 500 cc/min for
30 s before intranasal naloxone delivery. To ensure max-
imal delivery, animals remained in supine position during
naloxone administration. When the animals regained con-
sciousness, they were returned to the home cage. Nalox-
one solution was prepared fresh daily in sterile ultrapure
water and stored at room temperature between adminis-
trations. Using a Rainin LTS L-20 pipette and sterile pi-
pette tips, 10 l drug or vehicle was administered into
each nostril as described (Luo et al., 2013).
Implantation of mini-osmotic pumps for continuous
()-naloxone delivery
Two days after distal middle cerebral artery occlusion
(dMCAo) surgery, the rats were anaesthetized with chloral
hydrate (0.4 mg/kg i.p.) for mini-osmotic pump implanta-
tion (Alzet; model 2002). The pump was implanted under
the skin, and the catheter was inserted into the right
ventricle. The pumps were filled with vehicle (sterile,
ultrapure water) or ()-naloxone 96 mg/ml. The pump-
ing rate was 0.5 l/h, and the pumps were left in place
for 12 d.
Behavioral analysis
The elevated body swing test for body asymmetry (Bor-
longan et al., 1998), modified Bederson’s score (Bederson
et al., 1986), and measurement of locomotor activity were
performed as previously described (Airavaara et al., 2009,
2010). Briefly, body asymmetry was analyzed from 20
consecutive trials by suspending the rats 20 cm above the
testing table by lifting their tails and counting the fre-
quency of initial turnings of the head or upper body con-
tralateral to the ischemic side (the maximum impairment
in stroke animals is 20 contralateral turns, whereas naive
animals turn in each direction with equal frequency). For
Bederson’s score, neurologic deficits were scored using
the following criteria: 0, rats extend both forelimbs straight
when lifted by the tail, no observable deficit; 1, rat keeps
the one forelimb to the breast and extends the other
forelimb straight when lifted by the tail; 2, rat shows
decreased resistance to lateral push in addition to behav-
ior in score 1; 3, rat twists the upper half of the body when
lifted by the tail in addition to behavior in other scores.
Locomotor activity was measured for 24 h by placing the
rat in a 42  42  31-cm Plexiglas box with an infrared
activity monitor (Accuscan). All behavioral assessments
were performed in a blinded manner, and the experi-
menter did not know group allocation. Body asymmetry
and Bederson’s score were assessed at the middle of the
day, so that the animals had fully recovered from isoflu-
rane anesthesia needed for the period of intranasal ad-
ministration in the morning and evening.
Histology
The rats were deeply anaesthetized with pentobarbital
(90 mg/kg i.p.) and transcardially perfused with 200 ml
saline followed by 500 ml of 4% paraformaldehyde. Brains
were processed for either paraffin or free-floating sections
and stained with anti-Iba1, anti-CD68, anti-NeuN, anti-
GFAP, or anti-MBP antibodies.
Immunostaining of paraffin sections
Brains were postfixed in 4% paraformaldehyde for 2 d,
dehydrated in a series of ethanol and xylene, and embedded
in paraffin. Brains were cut into 5-m-thick sagittal sections
using a Leica HM355S microtome and mounted on Super-
frost Plus slides (Thermo Fisher Scientific). Sections were
deparaffinized, and antigen retrieval was performed by heating
in 0.05% citraconic anhydride (Sigma-Aldrich), pH 7.4. Endog-
enous peroxidase activity was blocked with 0.6% hydrogen
peroxide (Sigma-Aldrich), and nonspecific antibody binding
was blocked with 1.5% normal goat or horse serum (Vector
Laboratories), followed by incubation with primary antibody
(rabbit anti-Iba1 1:1000, #019-19741, RRID:AB_839504, Wako;
mouse anti-CD68 1:500, #MCA341R, RRID:AB_2291300,
AbD Serotec; mouse anti-GFAP 1:1000, #MAB360, RRID:
AB_2109815, Millipore; mouse anti-NeuN 1:200, #MAB377,
RRID:AB_2298772, Millipore; and rabbit anti-MBP 1:500,
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#ab40390, RRID:AB_1141521, Abcam) at 4°C overnight. The
next day, sections were incubated with secondary antibody
(goat anti-rabbit, RRID:AB_2336820, or horse anti-mouse,
RRID:AB_2336811, biotinylated secondary antibody 1:200,
Vector Laboratories) followed by incubation with avidin-biotin
complex (ABC kit, Vector Laboratories). Color was developed
using peroxidase reaction with 3=,3=-diaminobenzidine (DAB;
RRID:AB_2336382, Vector Laboratories). Cresyl violet staining
was used as background staining with anti-CD68. For immu-
nofluorescence staining, goat anti-rabbit Alexa Fluor 488 (1:
500, #A11034, RRID:AB_2576217, Life Technologies) and
goat anti-mouse Alexa Fluor 568 (1:500, #A11004, RRID:
AB_2534072, Life Technologies) were used as secondary an-
tibodies.
Immunostaining of free-floating sections
Brains were dehydrated in 30% sucrose at 4°C and sec-
tioned coronally into 40-m-thick slices using a Leica
CM3050 Cryostat. Sections were taken from 2.1 to –1.0 mm
(striatum) and –2.4 to –4.0 mm (thalamus) relative to bregma,
then stored in 1 PBS for short-term storage or cryopreser-
vant for long-term storage (20% glycerol, 2% DMSO in 1
PBS). Sections were blocked with 0.3% hydrogen peroxi-
dase and 4% BSA (Sigma-Aldrich)  0.3% Triton X-100
(Sigma-Aldrich), then incubated with primary antibody (rab-
bit anti-Iba1 1:2000, RRID:AB_839504; mouse anti-NeuN
1:1000, RRID:AB_2298772) overnight at 4°C. The next day,
sections were incubated with secondary antibody, followed
by incubation with avidin-biotin complex and DAB as above.
Unbiased stereological counting of Iba1 cells in the
striatum
Iba1-positive (Iba1) cells in the striatum were counted
from 40-m-thick free-floating sections using unbiased
stereology with a stereomicroscope (Olympus BX51) and
StereoInvestigator 6 program (MBF Bioscience) as previ-
ously described (Mijatovic et al., 2007). The optical frac-
tionator method, which involves a three-dimensional
probe for counting the cell of interest by randomly and
systematically sampling each section, was used. It is
unbiased, since it does not involve cell size and shape,
and is unaffected by tissue processing. Cell population is
computed from the volume fraction. The volume fraction
consists of information on the thickness of tissue sam-
pled, the number of sections sampled, and the area in
each section sampled. Three 40-m-thick coronal slices
were selected based on their relative location to bregma
(0.2, –0.26, and –0.4/–0.5 mm) to obtain results relatively
free of bias in the distribution of the cells. Only Iba1 cells
with clear microglia morphology were counted. The con-
tralateral and ipsilateral striata were first traced, and then
the area was analyzed for each slice. Approximately
60–80 randomly selected sites per area/slice were ana-
lyzed to ensure accuracy and minimize error.
Analysis of CD68, Iba1, and NeuN cells in the
thalamus
The number of CD68, Iba1, and NeuN cells in the
thalamus was analyzed using Image-Pro Analyzer 7.0
program. Slides were scanned with a 3DHISTECH Pan-
noramic 250 FLASH II digital slide scanner (scanning
service provided by the Institute of Biotechnology, Uni-
versity of Helsinki; http://www.biocenter.helsinki.fi/bi/
histoscanner/index.html), and 10 magnification images
of the thalamus were taken with Pannoramic Viewer ver-
sion 1.15.3. To estimate the number of immunopositive
cells in the ipsilateral thalamus, the thalamus was traced
and the Iba1 immunoreactive area was counted from 3–6
coronal sections (in 3 rats, there were only 2 sections
counted). The object count of NeuN cells in the thalamus
was counted from 4–6 coronal sections per brain. Sec-
tions were taken every 300–400 m between –2.4 and
–4.0 mm relative to bregma, and an average for each
brain was used for further analysis. The average number
of NeuN cells and the Iba1 immunoreactive area are
expressed as a percentage compared to the contralateral
side. To estimate the number of CD68 cells in the thal-
amus, the object count of CD68 cells was analyzed from
3–4 sagittal sections per hemisphere, taken every 500 m
between 1.9 and 3.4 mm or –1.9 and –3.4 mm relative to
bregma, and the average cell count per hemisphere was
used for further analysis.
Quantitation of infarction size
At day 14 post-stroke, the average infarction size was
quantified from 6 anti-NeuN–stained coronal brain sec-
tions, taken every 800 m between 1.80 and –3.00 mm
relative to bregma. The area devoid of NeuN cells and
the total area of the brain section were defined in Pan-
noramic Viewer version 1.15.3. Infarction size is ex-
pressed as a percentage of the total area of the section.
At day 2 post-stroke, the infarction volume was quantified
with 2,3,5-triphenyltetrazolium chloride (TTC) staining
from 2-mm brain slices as described previously (Airavaara
et al., 2009).
Measurement of TNF- secretion from microglia/
macrophages isolated from the stroke cortex
The CD11b immunopositive cortical microglia/macro-
phages were isolated by magnetic activated cell sorting
(MACS). The rats were anesthetized with pentobarbital (90
mg/kg i.p.) at 7 d post-stroke after 90 min dMCAo and
perfused with 200 ml saline. The ischemic cortex and the
corresponding contralateral cortex were dissected on ice
in HBSS without Ca2 and Mg2. The tissue was disso-
ciated using Neural Tissue Dissociation kit (Miltenyi Bio-
tec) and gentleMACS Dissociator (Miltenyi Biotec). After
dissociation, the cells were suspended in 0.5% BSA in
PBS and incubated with Myelin Removal Beads II (1:10,
Miltenyi Biotec) for 15 min at 4°C. The cells were washed
and resuspended in 0.5% BSA in PBS and filtered
through an LS column (Miltenyi Biotec) using a Quadro-
MACS Separator (Miltenyi Biotec). The total effluent was
collected and resuspended in 0.5% BSA with 2 mM EDTA
in PBS. The cells were incubated at 4°C for 10 min with
mouse anti-CD11b:FITC antibody (1:10, #MCA275FA,
RRID:AB_2129486, AbD Serotec). The cells were washed,
resuspended in 0.5% BSA with 2 mM EDTA in PBS,
and incubated with anti-FITC MicroBeads (1:10, RRID:
AB_244371, Miltenyi Biotec) for 15 min at 4°C. The cells
were washed and resuspended in 0.5% BSA with 2 mM
EDTA in PBS. The cell suspension was applied to an LS
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column placed on a QuadroMACS Separator, and the
magnetically labeled cells were used for additional exper-
iments. The cells were plated on poly-ornithine–coated
glass coverslips on a 48-well plate at the density of 30,000
cells/well in DMEM:F12 medium (Life Technologies) con-
taining 10% FBS and 0.2% primocin (InvivoGen). LPS or
naloxone was added immediately after plating. The cul-
ture medium was collected 20 h later and analyzed using
the Rat TNF alpha ELISA Ready-SET-Go! kit (#88-7340-
22, RRID:AB_2575088, eBioscience). The results are pre-
sented from 3 independent experiments. The CD11b
cells were isolated from 2–3 rats in each experiment. The
values for each well within an experiment were normalized
to the mean value of the control wells within the corre-
sponding experiment.
Experimental design and statistical analysis
All the experiments and analyses were performed in a
blinded manner. First, the time course of glial activation in
the dMCAo model was characterized. To minimize the
number of animals needed (n  24 in total; n  4 per
group), 90-min occlusion time was used to create a robust
lesion. Immunostaining of sagittal sections with anti-Iba1,
anti-CD68, and anti-GFAP antibodies was used to visual-
ize the temporal and spatial distribution of glial cells post-
stroke. As the dMCAo model is unilateral, the contralateral
hemisphere was used as a control after we confirmed that
the expression of glial cells in naive brain is similar to the
contralateral hemisphere of ischemic brain. For quantita-
tion of CD68 cells, 3–4 sections per animal per hemi-
sphere were used to result in an average.
Second, to test the efficacy of post-stroke ()-naloxone
(0.32 mg/kg; n  27), repeated dosing (twice a day for 7
d) was used owing to the short half-life of naloxone. To
make the setting clinically relevant, the treatment was
started 1 d after stroke and was given intranasally, and
a smaller infarct using 60-min dMCAo was induced.
Behavioral recovery was monitored for 14 d with body
asymmetry test, Bederson’s score, and measurement of
spontaneous locomotor activity. Vehicle (n  25) and
no-treatment groups (n  13) were used as a control in
the behavioral assays. As both naloxone enantiomers
have anti-inflammatory effects on microglia, only the (–)
form antagonizes opioid receptors. Thus, we included
also (–)-naloxone (n  7) group in the behavioral assays to
provide information about whether ()- and (–)-naloxone
have similar effects on recovery. The dose–response of
()-naloxone was tested in a separate experiment (0.0008
mg/kg, n  8; 0.008 mg/kg, n  8; 0.08 mg/kg, n  7; 0.8
mg/kg, n  8; vehicle, n  11). The amount of microglial
activation in the striatum and thalamus and neuronal loss
in the cortex and thalamus were analyzed with immuno-
histochemistry. For quantitation of Iba1 and NeuN
cells, 3–6 sections from corresponding coronal planes
from each animal were used.
Statistical analyses were performed with IBM SPSS
Statistics software version 24.0. Normal distribution of
each dataset was analyzed by Levene’s test for equality of
variances and analyzed with either one-way ANOVA or
Kruskal–Wallis nonparametric ANOVA, or with Student’s t
test or nonparametric Mann–Whitney U test in the case of
only two groups. One-way ANOVA was followed by Bon-
ferroni’s or Dunnett’s post hoc test and Kruskal–Wallis
test was followed by pairwise comparison with Mann–
Whitney U test. Since the immunohistochemical data did
not differ between the vehicle and no treatment groups or
between ()-naloxone doses 0.32 and 0.8 mg/kg, the two
groups were combined as one control group and one
()-naloxone group. Statistical significance was consid-
ered at p  0.05. The results are presented as mean 
SEM. Superscript letters listed with significance values
correspond to the statistical tests shown in Table 1.
Results
Long-lasting microglial and astrocyte activation in
the ipsilateral hemisphere after dMCAo
We first characterized the neuroinflammatory response
in proximal (cortex) and distal (thalamus) regions after
transient 90-min dMCAo, and second, tested the efficacy
of post-stroke intranasal naloxone treatment in adult rats
after 60 min dMCAo. At day 2 post-stroke, microglia/
macrophage activation was observed mainly in the peri-
infarct region, and few phagocytic CD68 cells (a marker
for activated, phagocytic microglia/macrophages) were
present (Fig. 2C, D). Microglia/macrophage activation
peaked on day 7 post-stroke in the ischemic cortex, when
the core area was filled with Iba1 cells (a marker for
all microglia/macrophages) and CD68 cells having a
phagocytic/macrophage-type morphology (Fig. 2Ea, Fa).
Microglia/macrophage activation was seen in the ipsilat-
eral striatum starting from post-stroke day 7 (Fig. 2Ec).
Interestingly, activated microglia/macrophages were
aligned along fiber bundles, with a “stream-like” formation
along the myelin embedded axons (Fig. 3). Iba1 cells
with activated morphology were evident in the ipsilateral
thalamus at day 7 post-stroke, but only a few cells were
CD68 (Fig. 2Ed, Fd, P). CD68 immunoreactivity in-
creased in the ipsilateral thalamus after post-stroke day 7,
peaked at days 14–28, and remained elevated until day
112 (H(11)  41.5, p  0.001,a Kruskal–Wallis, Fig. 2P).
These results suggest that inflammation in the thalamus is
long lasting and phagocytic cells are present in far distal
areas at least 4 mo after stroke (Fig. 2Nd, P). Neuronal
loss was observed in the ipsilateral thalamus at post-
stroke day 14 (Fig. 6B). At 112 d post-stroke, atrophy of
the thalamus due to shrinkage of the ipsilateral thalamus
was observed (Fig. 2Me, Ne; Fig. 4Ge). Analysis of spa-
tiotemporal activation of GFAP cells (a marker for astro-
cytes) revealed a pattern similar to that of microglia/
macrophage activation (Fig. 4). Similarly to microglia,
astrocytes in the ischemic core died during the first cou-
ple of days. Astrogliosis was found in the peri-infarct area
starting from day 2 post-stroke (Fig. 4Bb). There was clear
astrocytic scar formation in the peri-infarct region starting
from post-stroke day 7 (Fig. 4Cb, Ce). From day 7 on-
ward, astrogliosis was evident in the striatum and even in
the thalamus (Fig. 4C–G). Astrogliosis in the ipsilateral
thalamus persisted for up to 112 d post-stroke (Fig. 4Gd,
Ge), suggesting glial scar formation without local ischemic
damage.
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Post-stroke treatment with intranasal ()-naloxone
started on day 1 post-stroke promotes short-term
behavioral recovery, reduces neuronal loss, and
decreases microglial activation
The efficacy of post-stroke ()-naloxone treatment was
tested in rats (n  65), and treatment was initiated 1 d
after 60-min dMCAo, before extensive activation of mi-
croglia/macrophages, and it was continued for 7 d, i.e.,
the period when microglia/macrophage activation pro-
gresses in the ischemic region. One day post-stroke, the
rats were balanced into groups based on their neurologic
deficits as measured by body asymmetry and Bederson’s
score, and ()-naloxone (0.32 mg/kg) or vehicle was ad-
ministered intranasally every 12 h for 7 d (i.e., 14 doses
per animal, Fig. 5A). To identify the confounding effect of
isoflurane, two control groups were included: (i) stroke
rats receiving intranasal vehicle (including repeated iso-
flurane) and (ii) stroke rats with no intranasal treatment
and no isoflurane. There were no significant differences in
body asymmetry among the groups on days 1, 3, or 7
after dMCAob (Fig. 5B). However, on days 10 and 14
post-stroke, body asymmetry (H(2)  15.5, p  0.001 and
H(2)  12.3, p  0.002, respectively,b Kruskal–Wallis) and
neurologic deficits (H(2)  15.4, p  0.001 and H(2) 
19.1, p  0.001, respectivelyc) were significantly reduced
in the ()-naloxone treated rats (Fig. 5B, C). The reduction
in body asymmetry (H(4)  15.1, p  0.004,d Kruskal–
Wallis) and neurologic deficits (H(4)  6.38, p  0.041e)
was dose dependent (Fig. 5D, E). As another indicator of
hastened recovery, ()-naloxone improved locomotor ac-
tivity at day 14 post-stroke (H(2)  6.82, p  0.033,g
Kruskal–Wallis, Fig. 5G). Similarly, (–)-naloxone (0.32 mg/
Table 1. Statistical analysis
Location Dataset Data structure Type of test Power




H(11)  41.5, p  0.000; ipsilateral hemisphere: d2 vs. d7: p  0.021; d2 vs. d14: p  0.021;
d2 vs. d28: p  0.021; d2 vs. d56: p  0.021; d2 vs. d112: p  0.021; d7 vs. d14: p 
0.021; d7 vs. d28: p  0.021; d7 vs. d56: p  0.083; d7 vs. 112: p  0.083; d14 vs. d28:
p  1.00; d14 vs. d56: p  0.043; d14 vs. d112: p  0.021; d28 vs. d56: p  0.083; d28
vs. d112: p  0.043; d56 s. d112: p  0.773; ipsilateral vs. contralateral: d2: p  0.773;
d7: p  0.021; d14: p  0.021; d28: p  0.021; d56: p  0.021; d112: p  0.021
b Fig. 5B Non-normal distribution Kruskal–Wallis,
Mann–Whitney U
d1: H(2)  2.26, p  0.323; d3: H(2)  4.93, p  0.085; d7: H(2)  1.29, p  0.524; d10:
H(2)  15.5, p  0.000; NT vs. ()-Nal: p  0.006; Veh vs. ()-Nal: p  0.000; NT vs.
Veh: p  0.651; d14: H(2)  12.3, p  0.002; NT vs. ()-Nal: p  0.012; Veh vs. ()-Nal:
p  0.001; NT vs. Veh: p  0.485
c Fig. 5C Non-normal distribution Kruskal–Wallis,
Mann–Whitney U
d1: H(2)  3.25, p  0.197; d3: H(2)  6.92, p  0.032; NT vs. ()-Nal: p  0.017; Veh vs.
()-Nal: p  0.059; NT vs. Veh: p  0.393; d7: H(2)  3.26, p  0.196; d10: H(2)  15.4,
p  0.000; NT vs. ()-Nal: p  0.002; Veh vs. ()-Nal: p  0.002; NT vs. Veh: p  0.203;
d14: H(2)  19.1, p  0.000; NT vs. ()-Nal: p  0.000; Veh vs. ()-Nal: p  0.000; NT
vs. Veh: p  0.209
d Fig. 5D Non-normal distribution Kruskal–Wallis,
Mann–Whitney U
H(4)  15.1, p  0.004; Veh vs. 8  104: p  0.206; Veh vs. 8  103: p  0.966; Veh vs.
8  102: p  0.002; Veh vs. 8  101: p  0.059; 8  104 vs. 8  103: p  0.552; 8
 104 vs. 8  102: p  0.001; 8  104 vs. 8  101: p  0.019; 8  103 vs. 8 
102: p  0.031; 8  103 vs. 8  101: p  0.142; 8  102 vs. 8  101: p  0.488
e Fig. 5E Non-normal distribution Kruskal–Wallis,
Mann–Whitney U
H(4)  6.38, p  0.041; Veh vs. 8  104: p  0.690; Veh vs. 8  103: p  0.487; Veh vs.
8  102: p  0.016; Veh vs. 8  101: p  0.038; 8  104 vs. 8  103: p  0.314; 8
 104 vs. 8  102: p  0.006; 8  104 vs. 8  101: p  0.025; 8  103 vs. 8 
102: p  0.144; 8  103 vs. 8  101: p  0.208; 8  102 vs. 8  101: p  0.730
f Fig. 5F Normal distribution One-way ANOVA,
Bonferroni
F(2,42)  0.054; NT vs. ()-Nal: p  0.064; Veh vs. ()-Nal: p  0.242; NT vs. Veh: p  1.00




H(2)  6.82, p  0.033; NT vs. ()-Nal: p  0.004; Veh vs. ()-Nal: p  0.243; NT vs. Veh: p
 0.313
h Fig. 5H Non-normal distribution Mann–Whitney U d1: p  0.663; d3: p  0.663; d7: p  0.963; d10: p  0.001; d14: p  0.000
i Fig. 5I Non-normal distribution Mann–Whitney U d1: p  0.159; d3: p  0.401; d7: p  0.565; d10: p  0.002; d14: p  0.005
j Fig. 5J Normal distribution t test d7: t(16)  0.47, p  0.647; d14: t(16)  0.06, p  0.953
k Fig. 5K Normal distribution One-way ANOVA,
Bonferroni
d7: F(2,59)  5.27, p  0.008; NT vs. ()-Nal: p  0.574; Veh vs. ()-Nal: p  0.113; NT vs.
Veh: p  0.009; d14: F(2,62)  1.79, p  0.175
l Fig. 6A Normal distribution t test t(26)  2.51, p  0.019




H(2)  11.4, p  0.003; Naïve vs. Ctrl: p  0.002; Naïve vs. ()-Nal: p  0.157; Ctrl vs. ()-
Nal: p  0.036
n Fig. 7A Normal distribution One-way ANOVA,
Bonferroni
F(2,31)  8.63, p  0.001; Naïve vs. Ctrl: p  0.003; Naïve vs. ()-Nal: p  1.00; Ctrl vs. ()-
Nal: p  0.013




H(2)  5.77, p  0.056




H(2)  17.6, p  0.000; Naïve vs. Ctrl: p  0.000; Naïve vs. ()-Nal: p  0.001; Ctrl vs. ()-
Nal: p  0.027
q Fig. 8B Normal distribution t test t(13)  0.89, p  0.389
r Fig. 8D Non-normal distribution Mann–Whitney U d2: p  0.861; d6: p  0.825; d10: p  0.279; d16: p  0.066
s Fig. 8F Non-normal distribution Mann–Whitney U d1: p  0.800; d3: p  0.861; d7: p  0.516; d10: p  0.391; d14: p  0.694
t Fig. 8G Normal distribution Two-way RM ANOVA F(4,52)  0.29, p  0.88
u Fig. 9A Non-normal distribution
(unequal variances)
Mann–Whitney U p  0.006
v Fig. 9B Normal distribution One-way ANOVA,
Dunnett
F(6,54)  2.74, p  0.022; 20M (–)-Nal: p  0.669; 50M (–)-Nal: p  0.020; 100M (–)-Nal:
p  0.218; 20M ()-Nal: p  0.492; 50M ()-Nal: p  0.637; 100M ()-Nal: p 
0.006
()-Nal, ()-naloxone; (–)-Nal, (–)-naloxone; Ctrl, control; d, post-stroke day; NT, no treatment; RM, repeated measures; Veh, vehicle.
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kg, intranasally) induced behavioral recovery on days 10
and 14 post-stroke (n  18; p  0.001 and p  0.001,
respectively,h for body asymmetry test; and p  0.002
and p  0.005, respectively,i for Bederson’s score, Mann–
Whitney U test; Fig. 5H, I). It has been reported that
continuous administration of the opioid receptor antago-
nist (–)-naltrexone decreases body weight and appetite
(Atkinson, 1984). We found no effect on body weight with
naloxone treatmentj,k (Fig. 5J, K).
Post-stroke ()-naloxone (0.32–0.8 mg/kg) reduced in-
farction size on day 14 after dMCAo (t(26)  2.51, p 
0.019,l unpaired t test; Fig. 6A) and prevented delayed
neuronal death in the ipsilateral thalamus (H(2)  11.4,
p  0.003,m Kruskal–Wallis; Fig. 6B). We observed a
negative correlation between the number of neurons
(NeuN cells) in the ipsilateral thalamus and infarction size
(Pearson correlation R  –0.691, p  0.0001), showing
that the larger the lesion in the cortex, the more extensive
neuronal loss in the thalamus. ()-Naloxone significantly
decreased the Iba1 cell number in the ipsilateral striatum
at post-stroke day 14 (F(2,31)  8.63, p  0.001,n one-
way ANOVA; Fig. 7A). There was no statistical difference
in the contralateral striatumo (Fig. 7B). Similarly, a signif-
icant reduction of Iba1 immunoreactivity by ()-naloxone
was found in the ipsilateral thalamus (H(2)  17.6, p 
0.001,p Kruskal–Wallis; Fig. 7C).
Figure 2. Time course of microglia/macrophage activation after cortical stroke. Representative images of immunostaining for all
microglia/macrophages (Iba1) and phagocytic microglia/macrophages (CD68) from ischemic core (a), peri-infarct area (b), striatum (c),
thalamus (d), and whole brain (e) sagittal sections at 2 (C, D), 7 (E, F), 14 (G, H), 28 (I, J), 56 (K, L), and 112 (M, N) days after 90-min
dMCAO in rat. Control images (A, B) are from the contralateral hemisphere of the stroke brain. Scale bar is 50 m (high magnification)
and 2000 m (low magnification). O, Example image of anti-NeuN immunostaining at post-stroke day 2 showing in more detail
the regions a– d. P, Quantitation of CD68 cells in the thalamus (d) at different time points showing the accumulation and
clearance of phagocytic microglia/macrophages in the ipsilateral thalamus. , p  0.05 indicates statistical difference between
the ipsilateral thalamus at different time points; #, p  0.05 indicates statistical difference between the ipsilateral and
contralateral thalamus in each time point, Mann–Whitney U test after Kruskal–Wallis test; n  4 in each group. The data
represent mean  SEM.
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Pretreatment or delayed post-stroke treatment with
()-naloxone is not beneficial in dMCAo model
We tested the neuroprotective effect of ()-naloxone
(n  15) by giving ()-naloxone (0.32 mg/kg) or vehicle
intranasally three times: 12 and 1 h before 60-min dMCAo
and immediately after reperfusion (Fig. 8A). The infarction
volume was determined by TTC staining 2 d after stroke.
We found no significant differences in the infarction vol-
ume between the groups (p  0.389,q unpaired t test; Fig.
8B). To find out whether more delayed ()-naloxone treat-
ment would give similar effect on recovery as the treat-
ment started on post-stroke day 1, we administered ()-
naloxone (0.8 mg/kg) or vehicle intranasally twice daily
starting from day 3 after 60-min dMCAo and continuing
for 7 d (n  13; Fig. 8C). There was an evident recovery
effect over time in the body asymmetry test, but there
were no statistically significant differences between the
vehicle and ()-naloxone groupsr (Fig. 8D). On post-
stroke day 16, there was a tendency (p  0.066,r Mann–
Whitney U test) in the ()-naloxone group for milder
neurologic deficits in the body asymmetry test, but it did
not reach statistical significance. To study whether longer,
continuous administration of ()-naloxone would further
enhance recovery after 60-min dMCAo, we delivered ()-
naloxone (1.15 mg/24 h) or vehicle into the ventricle using
mini-osmotic pumps on post-stroke days 2–14 (n  15;
Fig. 8E). There was again evident recovery effect in the
body asymmetry test, but there were no differences be-
tween the vehicle and ()-naloxone groupss (Fig. 8F), nor
were there any differences in body weight between the
groupst (Fig. 8G).
Naloxone decreases TNF- secretion from
microglia/macrophages
To test whether naloxone enantiomers affect cytokine
secretion, we isolated CD11b microglia/macrophages
from the infarct area at day 7 post-stroke and measured
the secretion of TNF-, a cytokine with well-characterized
pro-inflammatory effects downstream of TLR4 signaling.
First, we tested whether the isolated cells respond to
treatment with LPS by increasing the secretion of TNF-.
Overnight treatment with LPS increased the amount of
secreted TNF- 3.5-fold (p  0.006,u Mann–Whitney U;
Fig. 9A), confirming that the isolated cell population had
properties characteristic of microglia and macrophages.
Overnight treatment with both naloxone enantiomers sig-
nificantly decreased the amount of TNF- in the culture
medium (F(6,54)  2.74, p  0.022,v one-way ANOVA;
Fig. 9B). (–)-Naloxone 50 M and ()-naloxone 100 M
decreased the unstimulated secretion of TNF- by 15%
compared with control.
Discussion
We show for the first time that intranasal post-stroke
administration of naloxone enantiomers reduces inflam-
mation and hastens recovery during short-term behavioral
monitoring. Our data support a therapeutic window for
initiation of twice daily ()-naloxone treatment between
16 and 36 h post-stroke and continuing the treatment for
7 d. Our study also indicates that modulation of microglia/
macrophage activation in the ischemic cerebral cortex
Figure 3. Activated microglia in the striatum are lined up
along axonal bundles after cortical stroke. Immunostaining of
rat striatum at post-stroke day 14 for phagocytic microglia/
macrophages (CD68; A) and all microglia/macrophages (Iba1;
B). C–F, Double immunofluorescence staining of rat striatum at
post-stroke day 14 for phagocytic microglia/macrophages
(CD68; red; D) and myelin (MBP; green; E) with DAPI (blue; F). In
A, B, scale bar is 200 m; in C–F, scale bar is 50 m.
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and remote regions in the striatum and thalamus is a
potential therapeutic drug strategy. Because microglia/
macrophages can phagocytose viable neurons after isch-
emia (Neher et al., 2013), neuroinflammation may lead to
secondary neuronal loss. An ischemic brain injury leads to
activation of microglia and the release of pro-infla-
Figure 4. Time course of astrocyte activation after cortical stroke. Representative images of immunostaining for astrocytes
(GFAP) from the ischemic core (a), peri-infarct area (b), striatum (c), and thalamus (d) at 2 (B), 7 (C), 14 (D), 28 (E), 56 (F), and 112 (G)
days after 90-min dMCAo in sagittal rat brain paraffin sections. Control images (A) are from the contralateral hemisphere of the stroke
brain. Scale bar is 50 m in high-magnification images and 2000 m in low-magnification images. The regions analyzed (a–d) are
shown in more detail in Fig. 2O.
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mmatory factors and further potentiates neuronal damage
days to weeks after dMCAo (Dirnagl et al., 1999). It has
been suggested that during an ischemic event, the brain
remains in a continual state of neurotoxicity and microglia
become overactivated, releasing pro-inflammatory fac-
tors that can contribute to further damage (Glass et al.,
2010). It is known that overreactive microglia can cause
increased levels of cytokines, specifically TNF- and
interleukin-1 and -6 (Lee et al., 1993; Block et al., 2007).
Therefore anti-inflammatory drugs, such as minocycline,
have been used to alleviate this neuroinflammation and
improve stroke outcome (Yrjanheikki et al., 1999). Liebigt
et al. (2012) have shown that post-stroke application of
minocycline and indomethacin in rats, combined with
rehabilitative training, produces improved functional re-
covery compared with training alone.
Our data indicate that twice-a-day post-stroke treat-
ment with ()-naloxone for a week improves short-term
behavioral recovery and reduces neuronal damage and
infarction size. The behavioral effect of ()-naloxone cor-
related with suppression of activated microglia in the
striatum and thalamus and was not observed until day 10
post-stroke, which suggests that ()-naloxone targets
delayed post-stroke pathophysiological mechanisms
such as inflammation. The administration of ()-naloxone
was targeted to the period when the number of activated
microglia/macrophages is peaking in the cerebral cortex
and before microglial activation is evident in the striatum
or thalamus. We therefore propose that dampening mi-
croglia/macrophage activation with post-stroke ()-
naloxone restricts inflammation to limit associated lesion
Figure 5. Post-stroke intranasal administration of naloxone
enantiomers promotes functional recovery. A, Experimental
timeline. Intranasal naloxone (or vehicle) was administered twice
daily for 7 d post-stroke. D1–D14, post-stroke days 1–14; B,
behavioral assay. B, C, Effects of ()-naloxone (0.32 mg/kg; n 
27), vehicle (n  25), and no treatment (n  13) on body asym-
metry (B) and Bederson’s neurologic score test (C). , p  0.01
and , p  0.001 indicate post hoc comparison between
()-naloxone and vehicle groups, and #, p  0.05, ##, p  0.01,
and ###, p  0.001 indicate post hoc analysis between ()-
naloxone and no-treatment groups with Mann–Whitney U test
after Kruskal–Wallis test. D, E, Effects of different doses of
()-naloxone, 0.0008 mg/kg (n  8), 0.008 mg/kg (n  8), 0.08
mg/kg (n  7), and 0.8 mg/kg (n  8), compared to vehicle (n 
11) on day 14 post-stroke on body asymmetry (D) and Beder-
son’s neurologic score test (E). , p  0.05 and , p  0.01
indicate pairwise comparison with vehicle; #, p  0.05 and ##, p 
0.01 indicate pairwise comparison with other ()-naloxone
doses with Mann–Whitney U test after Kruskal–Wallis test. F, G,
Effects of ()-naloxone (0.32 mg/kg; n  16), vehicle (n  16),
and no treatment (n  13) on vertical (F) and horizontal (G)
activity measured for 24 h on day 14. ##, p  0.01, Mann–
Whitney U test after Kruskal–Wallis test. H–J, Effects of (–)-
naloxone (0.32 mg/kg; n  7) and vehicle (n  11) on body
asymmetry test (H), Bederson’s neurologic score test (I), and
body weight (J). , p  0.01 and , p  0.001 indicate
comparison with vehicle group with Mann–Whitney U test. K,
Effects of ()-naloxone (0.32 mg/kg, n  27), vehicle (n  25),
and no treatment (n  13) on body weight on days 7 and 14
post-stroke. , p  0.01, one-way ANOVA, Bonferroni’s post
hoc test. The data represent mean  SEM.
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expansion that occurs up to 24–48 h after transient
MCAo (Li et al., 2000; Liu et al., 2009). This is further
supported by the fact that ()-naloxone treatment starting
on days 2–3 post-stroke did not have a significant effect
on recovery. Thus, the therapeutic window for ()-na-
loxone seems to be between 16 and 36 h post-stroke,
when there is not yet substantial activation of microglia.
However, when using mini-osmotic pumps, the drug ki-
netics and concentrations at the target tissues over the
administration period are only estimations until quantita-
tive assessments of delivery are performed. When the
intranasal ()-naloxone treatment was started at day 3
post-stroke and continued for 7 d, there was a trend for
milder neurologic deficits on day 16 post-stroke (p 
0.066). Because of the small number of animals, the data
are inconclusive and further studies are needed to fully
optimize the dosing and timing of administration. Yet,
prestroke treatment with ()-naloxone was not neuropro-
tective, as has been shown before by Liao et al. (2003),
supporting our hypothesis that ()-naloxone should be
administered during the inflammation period.
We also show that naloxone enantiomers decrease
unstimulated TNF- secretion from microglia/macro-
phages isolated from the stroke cortex at day 7 post-
stroke. Although the characteristics and phenotypes of
microglia are altered in in vitro conditions (Gosselin et al.,
2017), these data strengthen the view that ()-naloxone
can regulate the pro-inflammatory function of microglia/
macrophages. Moreover, microglia phenotype is highly
dependent on the environment where it is, and therefore
the data should be interpreted carefully. It is noteworthy
that this study is the first to show that (–)- or ()-naloxone
inhibits basal TNF- secretion from stroke-activated mi-
croglia/macrophages without extra stimulus.
The time course of microglial and astrocyte activation in
the thalamus after cortical stroke is less studied. We
observed activated microglia/macrophages and increased
GFAP immunoreactivity in the thalamus still at 4 mo post-
stroke, and indeed, also in the intraluminal MCAo model
microglial activation in the thalamus has been reported to
be long-lasting, for up to 6 mo post-stroke (Justicia et al.,
2008). However, in the intraluminal MCAo model, the
ischemic lesion is somewhat close to the thalamus and in
some cases extends into it. Microglia and astrocytes have
been shown to be activated already after day 3 post-
stroke in the ipsilateral thalamus in the transient intralu-
minal MCAo model (Loos et al., 2003). In our model,
microglial and astrocyte activation was evident in the
ipsilateral thalamus at 7 d post-stroke, but interestingly,
microglia were not phagocytic until day 14. Previously, it
has been reported that neuronal degeneration in the ipsi-
lateral thalamus is evident at 14 d post-stroke in the
transient intraluminal MCAo model (Loos et al., 2003),
similar to our findings. The ischemia-induced neuronal
loss and microglia/macrophage activation in the thalamus
probably reflects retrograde/anterograde degeneration
caused by cortical damage. However, inflammation has
been implicated in secondary neurodegeneration (Block
et al., 2005; Schroeter et al., 2006), and ()-naloxone
reduces inflammation and neurodegeneration at both pri-
mary (cortex) and secondary (thalamus) sites of injury.
Although it remains unclear whether the beneficial effects
of ()-naloxone occur directly in cells in the thalamus or
indirectly by reducing inflammation in the cortex, or both,
intranasal ()-naloxone is apparently beneficial to recov-
ery from stroke. The thalamus regulates multiple sensory
and motor functions that are also controlled by other brain
regions. Furthermore, the thalamus is a relay station con-
necting the right and left hemispheres, and a unilateral
lesion of the thalamus usually has little behavioral conse-
quences (Carrera and Bogousslavsky, 2006). Overall, the
role of thalamic neurodegeneration and inflammation fol-
lowing cortical infarction remains unclear, and it is not
known whether the secondary pathology affects behav-
ioral recovery. Our study supports the need for future
research into the role of thalamic injury in cortical stroke.
Single ()-naloxone doses that had effect on recovery
in our study were 0.08 mg/kg, 0.32 mg/kg, and 0.8 mg/kg.
As a comparison, the FDA-approved Narcan nasal spray
to treat opioid overdose contains 4 mg of (–)-naloxone
hydrochloride, being equivalent to 0.08 mg/kg dose for a
person weighing 50 kg. Based on pharmacokinetic data
on naloxone (Dowling et al., 2008; Krieter et al., 2016), we
Figure 6. Post-stroke intranasal ()-naloxone decreases in-
farction area and neuronal loss in the thalamus. A, Average
infarction size calculated from NeuN-negative area at day 14
post-stroke. , p  0.05, Student’s t test. B, Average number of
neurons (NeuN cells) in the ipsilateral thalamus at day 14
post-stroke expressed as a percentage of the contralateral thal-
amus. , p  0.05 and , p  0.01 indicate pairwise comparison
with the control group with Mann–Whitney U test following
Kruskal–Wallis test. C, Representative photomicrographs of anti-
NeuN immunostained brain sections, with infarction area delin-
eated. D–F, Representative photomicrographs of anti-NeuN
immunostaining of ipsilateral thalamus in naive (D), control (E),
and ()-naloxone–treated (F) rats. Scale bar is 150 m. Naive,
no-stroke rats (n  6); control, stroke rats with vehicle or no
treatment (n  18); ()-naloxone, 0.32–0.8 mg/kg (n  10). The
data represent mean  SEM.
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estimated that ()-naloxone levels in rat brain reached
nanomolar concentrations. The pharmacokinetic profile of
naloxone is favorable for stroke treatment, since it is
efficiently transported to the brain. However, its short
elimination half-life [1.57  0.784 h (Lewis et al., 2012)]
requires repeated dosing. Short-term (up to 2 d post-
stroke) intravenous (–)-naloxone (dose from 0.4 to 4 mg)
has been tested in patients having an acute ischemic
stroke, and it has rapidly, within minutes, improved neu-
rologic deficits (Baskin and Hosobuchi, 1981; Jabaily and
Davis, 1984). However, later clinical studies on the effi-
cacy of naloxone have been inconclusive. A phase II open
trial studying the safety of a high loading dose followed by
24-h infusion of (–)-naloxone did not find benefit at 3 mo
post-stroke when the treatment was started within 48 h of
stroke onset (Olinger et al., 1990). A subsequent double-
blind, randomized pilot trial using the 24-h infusion found
no significant differences between the naloxone and pla-
cebo groups when the treatment was initiated within 12 h
of the onset of symptoms (Federico et al., 1991). At the
time when these studies were performed, the anti-
inflammatory effects of naloxone were not known. The
lack of effect in these clinical studies may have resulted
from the short treatment regimen. Treatment for only 24 h
may not be enough to dampen the post-stroke microglial
response. Moreover, the clinical studies have been based
on the assumption that opioid antagonism is at least
partly behind the beneficial effect of naloxone in acute
stroke that was reported in the early case studies in the
1980s. In our experiment, both ()- and (–)-naloxone had
a similar effect on recovery starting from post-stroke day
10 onward, implying that opioid receptor antagonism is
not necessary for the recovery promoting effect in the
chronic phase of stroke. Thus, we propose additional
clinical studies that would use different dosing paradigms
to optimize the post-stroke ()-naloxone dosing regimen.
The Stroke Therapy Academic Industry Roundtable
(STAIR) recommendations to improve the quality of pre-
clinical stroke studies emphasize the importance of dose–
response and therapeutic window studies together with
histologic and functional outcome monitoring. According
to STAIR recommendations, the therapies should be
tested in several animal species using both sexes as well
as aged and comorbid animals. Therefore, we warrant
further studies using ()-naloxone for stroke treatment in
female, aged, and comorbid animals to better reflect the
Figure 7. Post-stroke intranasal ()-naloxone decreases microglia/macrophage activation in the striatum and thalamus. A, B,
Microglia/macrophages (Iba1 cells) were counted with unbiased stereology in the ipsilateral (A) and contralateral (B) striatum. , p
 0.05 and , p  0.01 indicate pairwise comparison with the control group with Bonferroni’s post hoc test following one-way
ANOVA. C, The area of Iba1 cells in the ipsilateral thalamus expressed as a percentage of the contralateral thalamus. , p  0.05
and , p  0.001 indicate pairwise comparison with the control group; ##, p  0.01 indicates comparison with the naive group with
Mann–Whitney U test following Kruskal–Wallis test. D–K, Representative photomicrographs of anti-Iba1 immunostaining of ipsilateral
striatum (D, E) and thalamus (F, G) in control (D, F) and ()-naloxone–treated (E, G) rats; H–K show high magnification. Black arrow
shows a typical Iba1 cell. Scale bars are 1000 m (D–G) and 50 m (H–K). Naive, no-stroke rats (n  6); control, stroke rats with
vehicle or no treatment (n  18); ()-naloxone, 0.32–0.8 mg/kg (n  10). The data represent mean  SEM.
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clinical situation within the heterogeneous patient popu-
lation. Also, behavioral testing should be conducted for
	14 d to confirm the beneficial effect of ()-naloxone on
long-term behavioral recovery. Regarding the safety of
naloxone therapy, naloxone has been already shown to
be safe and well tolerated in patients with the correspond-
ing dose range we have been using in rats.
In conclusion, characterization of the neuroinflamma-
tory response in rat cortical stroke revealed long-lasting
microglia/macrophage and astrocyte activation as well as
neuronal death in the ipsilateral thalamus. Phagocytic
cells were present in the thalamus for up to 4 mo post-
stroke. This delayed neuronal loss and phagocytosis in
the thalamus could serve as a new target for drug treat-
ment after stroke with a larger therapeutic window than
exists for current post-stroke treatment (i.e., tissue plas-
minogen activator). Most importantly, we found that inter-
mittent post-stroke intranasal ()-naloxone treatment
starting on day 1 post-stroke promoted short-term behav-
ioral recovery, reduced microglial activation in the stria-
tum and thalamus, and decreased neuronal loss in the
cortex and thalamus. It is likely that ()-naloxone medi-
ates its positive effects on stroke via mechanisms where
TLR signaling and reduction of oxidative stress are in-
volved. ()-Naloxone is thus a promising drug for the
treatment of ischemic stroke.
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